[Mesoglycan in acute focal cerebral ischemia].
An open, randomized, controlled study including 57 patients with acute cerebral infarct was performed. All the patients, followed and controlled by the same examiner, received, in the first ten days, 24 mg/die i.v. of dexamethasone. 28 patients were also treated with mesoglycan (150 mg/die i.m. for five days and 144 mg/die per os for a further twenty-five days). The differences between the basal and final scores in the mesoglycan group and in the controls were not statistically significant as analysed by the Mann-Whitney U test. The mesoglycan influenced only slightly the laboratory values (PT, PTT, alkaline phosphatase, GOT, GPT, cholesterol and triglycerides, fibrinogen, blood glucose, azotemia and creatinine) performed before the beginning of the treatment, as their changes after thirty days of therapy were in the normal range. The mesoglycan was very well tolerated and no side-effects were observed during the treatment.
Cazzato
G
G
Clinica Neurologica dell'Università di Trieste.
Zorzon
M
M
Masé
G
G
Antonutti
L
L
Iona
L G
LG
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy*; D002544:Cerebral Infarction / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D006025:Glycosaminoglycans; D003907:Dexamethasone; C040617:mesoglycan
Il mesoglicano nelle ischemie cerebrali acute a focolaio.